Dysregulation of TMPRSS3 and TNFRSF11B correlates with tumorigenesis and poor prognosis in patients with breast cancer

Luo,Ping; Lu,Gaixia; Fan,Lin‑Lin; Zhong,Xiaoming; Yang,Huiqiong; Xie,Ruting; Lv,Zhongwei; Lv,Qian‑Zhou; Fu,Da; Yang,Li‑Xin; Ma,Yushui

doi:10.3892/or.2017.5449

Dysregulation of TMPRSS3 and TNFRSF11B correlates with tumorigenesis and poor prognosis in patients with breast cancer

Authors:
- Ping Luo
- Gaixia Lu
- Lin‑Lin Fan
- Xiaoming Zhong
- Huiqiong Yang
- Ruting Xie
- Zhongwei Lv
- Qian‑Zhou Lv
- Da Fu
- Li‑Xin Yang
- Yushui Ma
View Affiliations

Affiliations: Department of Breast Cancer, Nanchang Third Hospital, Nanchang, Jiangxi 330002, P.R. China, Department of Nuclear Medicine, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China, Department of Radiology, Jiangxi Provincial Tumor Hospital, Nanchang, Jiangxi 330029, P.R. China, Department of Thoracic Surgery, Changhai Hospital of Second Military Medical University, Shanghai 200433, P.R. China
Published online on: February 14, 2017 https://doi.org/10.3892/or.2017.5449
Pages: 2057-2062

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was carried out to investigate the clinical significance of TMPRSS3 and TNFRSF11B in breast cancer. Thus, the expression levels of TMPRSS3 and TNFRSF11B and the correlation with prognosis in patients with breast cancer were analyzed in silico using gene microarray and hierarchical clustering analysis. Then, the differential expression in breast cancer vs. normal breast tissue was explored in the Oncomine platform and verified in our independent samples using IHC technique. Our results indicated that TMPRSS3 was upregulated and TNFRSF11B was downregulated in breast cancer tissues compared with the levels in the human normal breast tissues. TMPRSS3 and TNFRSF11B were confirmed to be correlated with distant organ metastasis of breast cancer. Moreover, upregulation of TMPRSS3 accompanied by downregulation of TNFRSF11B was found to be associated with a shorter median overall survival and indicated a poor prognosis. In conclusion, TMPRSS3 and TNFRSF11B may have potential prognostic value to be used as tumor biomarkers in breast cancer patients.

View Figures

View References

1	Nattinger AB and Mitchell JL: Breast cancer screening and prevention. Ann Intern Med. 164:ITC81–ITC96. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
4	Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, et al: Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib. JAMA Oncol. 2:1287–1294. 2016. View Article : Google Scholar : PubMed/NCBI
5	Maciejczyk A: New prognostic factors in breast cancer. Adv Clin Exp Med. 22:5–15. 2013.PubMed/NCBI
6	Recondo G Jr, de la Vega M, Galanternik F, Díaz-Cantón E, Leone BA and Leone JP: Novel approaches to target HER2-positive breast cancer: Trastuzumab emtansine. Cancer Manag Res. 8:57–65. 2016.PubMed/NCBI
7	Bianco S and Gévry N: Endocrine resistance in breast cancer: From cellular signaling pathways to epigenetic mechanisms. Transcription. 3:165–170. 2012. View Article : Google Scholar : PubMed/NCBI
8	Giessrigl B, Schmidt WM, Kalipciyan M, Jeitler M, Bilban M, Gollinger M, Krieger S, Jäger W, Mader RM and Krupitza G: Fulvestrant induces resistance by modulating GPER and CDK6 expression: Implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 109:2751–2762. 2013. View Article : Google Scholar : PubMed/NCBI
9	Marquette C and Nabell L: Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol. 13:263–275. 2012. View Article : Google Scholar : PubMed/NCBI
10	Wallrapp C, Hähnel S, Müller-Pillasch F, Burghardt B, Iwamura T, Ruthenbürger M, Lerch MM, Adler G and Gress TM: A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 60:2602–2606. 2000.PubMed/NCBI
11	Zhang D, Qiu S, Wang Q and Zheng J: TMPRSS3 modulates ovarian cancer cell proliferation, invasion and metastasis. Oncol Rep. 35:81–88. 2016.PubMed/NCBI
12	Rui X, Li Y, Jin F and Li F: TMPRSS3 is a novel poor prognostic factor for breast cancer. Int J Clin Exp Pathol. 8:5435–5442. 2015.PubMed/NCBI
13	Pelkonen M, Luostari K, Tengström M, Ahonen H, Berdel B, Kataja V, Soini Y, Kosma VM and Mannermaa A: Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival. BMC Cancer. 15:4312015. View Article : Google Scholar : PubMed/NCBI
14	Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
15	Dougall WC and Chaisson M: The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 25:541–549. 2006. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME and Yu J: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 365:671–679. 2005. View Article : Google Scholar : PubMed/NCBI
17	van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347:1999–2009. 2002. View Article : Google Scholar : PubMed/NCBI
18	Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, et al: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 534:47–54. 2016. View Article : Google Scholar : PubMed/NCBI
19	Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL and Massagué J: Genes that mediate breast cancer metastasis to lung. Nature. 436:518–524. 2005. View Article : Google Scholar : PubMed/NCBI
20	Park HR, Min SK, Cho HD, Kim DH, Shin HS and Park YE: Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J Korean Med Sci. 18:541–546. 2003. View Article : Google Scholar : PubMed/NCBI
21	Suva LJ, Washam C, Nicholas RW and Griffin RJ: Bone metastasis: Mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 7:208–218. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chen X, Lu J, Ji Y, Hong A and Xie Q: Cytokines in osteoblast-conditioned medium promote the migration of breast cancer cells. Tumour Biol. 35:791–798. 2014. View Article : Google Scholar : PubMed/NCBI
23	Hooper JD, Clements JA, Quigley JP and Antalis TM: Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem. 276:857–860. 2001. View Article : Google Scholar : PubMed/NCBI
24	Luostari K, Hartikainen JM, Tengström M, Palvimo JJ, Kataja V, Mannermaa A and Kosma VM: Type II transmembrane serine protease gene variants associate with breast cancer. PLoS One. 9:e1025192014. View Article : Google Scholar : PubMed/NCBI